|
University of California, Los Angeles |
Yvonne Chen |
Therapeutic Translational Research Projects |
BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
|
Neurona Therapeutics |
Cory Nicholas |
Therapeutic Translational Research Projects |
Development of a human stem cell-derived inhibitory neuron therapeutic for the treatment of chronic focal epilepsy |
$4,848,505 |
|
Stanford University |
Rosa Bacchetta |
Late Stage Preclinical Projects |
IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome |
$5,002,496 |
|
jCyte, Inc |
Henry Klassen |
Clinical Trial Stage Projects |
A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa |
$6,608,592 |
|
Cedars-Sinai Medical Center |
Clive Svendsen |
Clinical Trial Stage Projects |
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
|
University of California, Los Angeles |
Sophie Deng |
Clinical Trial Stage Projects |
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
|
City of Hope, Beckman Research Institute |
Saul Priceman |
Clinical Trial Stage Projects |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
|
University of Southern California |
Mark Humayun |
Therapeutic Translational Research Projects |
PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration |
$3,733,556 |
|
University of California, Irvine |
Brian Cummings |
Therapeutic Translational Research Projects |
An optimized human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) |
$4,804,737 |
|
University of California, San Diego |
Mark Tuszynski |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,235,897 |
|
Sanford Burnham Prebys Medical Discovery Institute |
Evan Snyder |
Therapeutic Translational Research Projects |
Human Neural Stem Cells (hNSCs) for neuroprotection in perinatal hypoxic-ischemic brain injury (HII)-Pre-IND-enabling Studies |
$4,963,684 |
|
University of California, Davis |
Mehrdad Abedi |
Conference - The Alpha Stem Cell Clinic Annual Symposium |
CIRM - Leading the New Era of Living Medicines |
$6,738 |
|
University of California, San Diego |
Stephanie Cherqui |
Clinical Trial Stage Projects |
Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
|
University of California, San Francisco |
Peter Stock |
Clinical Trial Stage Projects |
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$11,083,012 |
|
Aspen Neuroscience |
Andres Bratt-Leal |
Progression Award - Discovery Stage Research Projects |
Autologous therapy for Parkinson's disease: single cell RNAseq for in depth characterization of transplanted cells |
$177,579 |
|
Rocket Pharmaceuticals, Inc. |
Kinnari Patel |
Clinical Trial Stage Projects |
LADICell |
$5,867,085 |
|
University of California, San Francisco |
Mark Walters |
Late Stage Preclinical Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$2,242,805 |
|
University of California, Los Angeles |
Theodore Nowicki |
Clinical Trial Stage Projects |
Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,230,000 |
|
California State University San Marcos Corporation |
Bianca Mothe |
Conference - Manage The Bridges Annual Meeting |
2020 and 2021 Bridges Annual Meeting |
$125,180 |
|
Ankasa Regenerative Therapeutics, Inc. |
Ying Zhu |
Late Stage Preclinical Projects |
IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly |
$3,987,693 |
|
Stanford University |
Judith Shizuru |
Clinical Trial Stage Projects |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$1,113,487 |
|
Jasper Therapeutics, Inc. |
Wendy Pang |
Clinical Trial Stage Projects |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$2,313,398 |
|
University of California, Irvine |
Leslie Thompson |
Late Stage Preclinical Projects |
An hESC-derived hNSC Therapeutic for Huntington’s Disease |
$5,635,393 |
|
Stanford University |
Everett Meyer |
Clinical Trial Stage Projects |
Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$11,955,585 |
|
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 |
$6,192,579 |
|
University of California, Davis |
Diana Farmer |
Late Stage Preclinical Projects |
Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair |
$5,615,207 |
|
Pathways to Stem Cell Science |
Victoria Fox |
Conference - Manage The SPARK Annual Meeting |
2019 SPARK Annual Meeting |
$49,915 |
|
University of Southern California |
Neil Segil |
Quest - Discovery Stage Research Projects |
A screen for drugs to protect against chemotherapy-induced hearing loss, using sensory hair cells derived by direct lineage reprogramming from hiPSCs |
$741,574 |
|
Stanford University |
Alan Cheng |
Quest - Discovery Stage Research Projects |
Modulation of the Wnt pathway to restore inner ear function |
$1,389,416 |
|
City of Hope, Beckman Research Institute |
Xiuli Wang |
Late Stage Preclinical Projects |
CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS |
$3,812,797 |
|
University of California, San Francisco |
Karin Gaensler |
Therapeutic Translational Research Projects |
Developing engineered autologous leukemia vaccines to target residual leukemic stem cells |
$4,171,728 |
|
University of California, Los Angeles |
Steven Schwartz |
Therapeutic Translational Research Projects |
Clinical Translation of Autologous Regenerative Cell Therapy for Blindness |
$5,068,026 |
|
Stanford University |
Theodore Leng |
Therapeutic Translational Research Projects |
NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
|
University of California, San Diego |
Jonathan Lin |
Quest - Discovery Stage Research Projects |
Small Molecule Proteostasis Regulators to Treat Photoreceptor Diseases |
$1,153,937 |
|
Children's Hospital of Los Angeles |
Mark Frey |
Quest - Discovery Stage Research Projects |
Universal Pluripotent Liver Failure Therapy (UPLiFT) |
$1,297,512 |
|
Scripps Research Institute |
Stuart Lipton |
Quest - Discovery Stage Research Projects |
Drug Development for Autism Spectrum Disorder Using Human Patient iPSCs |
$1,827,576 |
|
Stanford University |
Philip Beachy |
Quest - Discovery Stage Research Projects |
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
|
University of California, San Francisco |
Mark Walters |
Conference - The 2019 Alpha Stem Cell Clinic Annual Symposium |
2019 Alpha Stem Cell Clinic Symposium - Mending Stem Cells: The Past, Present & Future Regenerative Medicine |
$60,000 |
|
Poseida Therapeutics, Inc. |
Devon Shedlock |
Late Stage Preclinical Projects |
Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer |
$3,992,090 |
|
University of California, San Francisco |
Hideho Okada |
Quest - Discovery Stage Research Projects |
Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
|
City of Hope, Beckman Research Institute |
Saul Priceman |
Quest - Discovery Stage Research Projects |
Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,351,174 |
|
Stanford University |
Katja Weinacht |
Quest - Discovery Stage Research Projects |
Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
|
University of California, San Diego |
Eric Adler |
Quest - Discovery Stage Research Projects |
Genetically Modified Hematopoietic Stem Cells for the Treatment of Danon Disease |
$1,393,200 |
|
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
|
Gladstone Institutes, J. David |
Li Gan |
Quest - Discovery Stage Research Projects |
Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia |
$1,547,157 |
|
Salk Institute for Biological Studies |
Ronald Evans |
Quest - Discovery Stage Research Projects |
Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes |
$1,637,209 |
|
University of California, San Francisco |
Krystof Bankiewicz |
Late Stage Preclinical Projects |
MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson's disease |
$5,811,340 |
|
City of Hope, Beckman Research Institute |
John Zaia |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
|
MAX BioPharma, Inc. |
Farhad Parhami |
Therapeutic Translational Research Projects |
Therapeutic development of Oxy200, an oxysterol with bone anabolic and anti-resorptive properties for intervention in osteoporosis |
$1,400,000 |
|
University of California, Irvine |
Magdalene Seiler |
Therapeutic Translational Research Projects |
Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models |
$4,769,039 |
|
Stanford University |
Bertha Chen |
Therapeutic Translational Research Projects |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
|
UCSF Benioff Children’s Hospital Oakland |
Henry Erlich |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$1,074,177 |
|
University of California, San Francisco |
Steven Mack |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$633,014 |
|
University of California, Los Angeles |
Steven Dubinett |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
|
University of California, San Francisco |
Morton Cowan |
Clinical Trial Stage Projects |
Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
|
Stanford University |
David Miklos |
Clinical Trial Stage Projects |
Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
|
Sangamo BioSciences, Inc. |
Bettina Cockroft |
Clinical Trial Stage Projects |
A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia |
$5,150,000 |
|
Fate Therapeutics, Inc. |
Bob Valamehr |
Late Stage Preclinical Projects |
IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell |
$4,000,000 |
|
City of Hope, Beckman Research Institute |
De-Fu Zeng |
Clinical Trial Stage Projects |
Treatment of sickle cell disease by induction of mixed chimerism and immune tolerance using CD4+ T-depleted haploidentical blood stem cell transplant |
$4,352,180 |
|
Medeor Therapeutics, Inc. |
Daniel Brennan |
Clinical Trial Stage Projects |
Cellular Immunotherapy for Induction of Immune Tolerance in HLA Matched Living Donor Kidney Transplant Recipients |
$11,217,155 |
|
Stanford University |
Joseph Wu |
Conference II |
2018 Stanford Drug Discovery and Stem Cell Technology Conference |
$15,000 |
|
The Regents of the University of California on behalf of its Riverside Campus |
Xiaoping Hu |
Conference II |
19th Annual UC System-wide Bioengineering Symposium |
$14,536 |
|
University of California, Los Angeles |
John Adams |
Conference - The 2018 Alpha Stem Cell Clinic Annual Symposium |
Delivery of Stem Cell Therapeutics to Patients |
$60,000 |
|
University of California, Irvine |
Leslie Thompson |
Conference II |
Stem Cells for Huntington’s Disease (HD) International (SC4HDI) Conference |
$31,727 |
|
Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
iPSCs: A Decade of Progress and Beyond |
$35,000 |
|
University of California, San Francisco |
David Rowitch |
Conference II |
“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” - 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) |
$10,000 |
|
International Society for Stem Cell Research |
Glori Rosenson |
Conference II |
ISSCR 2019 Nucleus Forum |
$24,000 |
|
International Society for Stem Cell Research |
Cathy Vijeh |
Conference II |
ISSCR 2019 |
$50,000 |
|
University of California, San Diego |
Yang Xu |
Quest - Discovery Stage Research Projects |
Development of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs |
$1,924,791 |
|
ViaCyte, Inc. |
Alan Agulnick |
Quest - Discovery Stage Research Projects |
Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes |
$1,470,987 |
|
Stanford University |
Helen Blau |
Quest - Discovery Stage Research Projects |
Stimulating endogenous muscle stem cells to counter muscle atrophy |
$2,198,687 |
|
University of California, San Diego |
Mark Tuszynski |
Quest - Discovery Stage Research Projects |
Neural Stem Cell Relays for Severe Spinal Cord Injury |
$1,638,900 |
|
Stanford University |
Kyle Loh |
Quest - Discovery Stage Research Projects |
Towards hepatocyte cell replacement therapy: developing a renewable source of human hepatocytes from pluripotent stem cells |
$1,968,456 |
|
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
Identification and Generation of Long Term Repopulating Human Muscle Stem Cells from Human Pluripotent Stem Cells |
$2,148,519 |
|
University of California, Los Angeles |
Stanley Carmichael |
Quest - Discovery Stage Research Projects |
iPS Glial Therapy for White Matter Stroke and Vascular Dementia |
$2,086,130 |
|
University of California, San Diego |
Tannishtha Reya |
Quest - Discovery Stage Research Projects |
Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
|
University of California, Los Angeles |
Scott Kitchen |
Quest - Discovery Stage Research Projects |
Engineering Lifelong Cellular Immunity to HIV |
$1,701,178 |
|
University of California, San Francisco |
Shuvo Roy |
Quest - Discovery Stage Research Projects |
Silicon Nanopore Membrane encapsulated enriched-Beta Clusters for Type 1 Diabetes treatment |
$1,113,000 |
|
University of California, Irvine |
Aileen Anderson |
Quest - Discovery Stage Research Projects |
Generation and in vitro profiling of neural stem cell lines to predict in vivo efficacy for chronic cervical spinal cord injury. |
$1,575,613 |
|
City of Hope, Beckman Research Institute |
Saswati Chatterjee |
Quest - Discovery Stage Research Projects |
Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A |
$2,182,193 |
|
Neurona Therapeutics |
Cory Nicholas |
Quest - Discovery Stage Research Projects |
Development of a Cellular Therapeutic for Treatment of Epilepsy |
$1,616,536 |
|
University of California, San Francisco |
Semil Choksi |
Inception - Discovery Stage Research Projects |
Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration |
$238,408 |
|
Stanford University |
Guillem Pratx |
Inception - Discovery Stage Research Projects |
Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET |
$229,227 |
|
University of California, Davis |
Alyssa Panitch |
Inception - Discovery Stage Research Projects |
Development of treatments to improve healing of ischemic wounds |
$235,099 |
|
University of California, San Diego |
Gerald Morris |
Inception - Discovery Stage Research Projects |
Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy |
$193,500 |
|
Stanford University |
Hiromitsu Nakauchi |
Inception - Discovery Stage Research Projects |
Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion |
$210,906 |
|
Human BioMolecular Research Institute |
John Cashman |
Inception - Discovery Stage Research Projects |
Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication |
$303,785 |
|
Loma Linda University |
Julia Unternaehrer-Hamm |
Inception - Discovery Stage Research Projects |
Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer |
$172,870 |
|
University of California, Davis |
Alice Tarantal |
Inception - Discovery Stage Research Projects |
Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies |
$235,800 |
|
Palo Alto Veterans Institute for Research |
Ngan Huang |
Inception - Discovery Stage Research Projects |
iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm |
$172,621 |
|
Loma Linda University |
David Baylink |
Inception - Discovery Stage Research Projects |
Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy |
$178,967 |
|
Cedars-Sinai Medical Center |
Dmitriy Sheyn |
Inception - Discovery Stage Research Projects |
IVD rejuvenation using iPSC-derived notochordal cells |
$241,992 |
|
Zenobia Therapeutics |
Vicki Nienaber |
Inception - Discovery Stage Research Projects |
A new phenotypic screening platform that identifies biologically-relevant targets and lead compounds for the treatment of Parkinson’s disease |
$112,500 |
|
University of California, Los Angeles |
Alireza Moshaverinia |
Inception - Discovery Stage Research Projects |
Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration |
$194,483 |
|
Stanford University |
Anthony Oro |
Therapeutic Translational Research Projects |
DEBCT: Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa |
$5,107,353 |
|
University of California, San Diego |
Karl Wahlin |
Inception - Discovery Stage Research Projects |
An IPSC cell based model of macular degeneration for drug discovery. |
$232,200 |
|
University of California, San Diego |
Catriona Jamieson |
Therapeutic Translational Research Projects |
A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia |
$2,511,767 |
|
University of California, San Diego |
Dan Kaufman |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment |
$3,260,000 |
|
Calibr |
Kristen Johnson |
Clinical Trial Stage Projects |
Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
|
Children's Hospital of Los Angeles |
Michael Pulsipher |
Clinical Trial Stage Projects |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
